IL-17A抑制剂治疗银屑病诱导或继发其他皮肤病研究进展

Research Progress on IL-17A Inhibitors for the Treatment of Psoriasis In⁃duced or Secondary Other Skin Diseases

银屑病是皮肤疾病中的世界性难题,白细胞介素17A(interleukin 17A, IL-17A)抑制剂的研发突破了银屑病治疗的技术难点,表现出迅速、持久的疗效,目前已得到普遍认可并广泛应用。然而临床实践中,部分银屑病患者在接受IL-17A抑制剂治疗后会出现其他皮肤病或以皮损为表现的疾病。现对国内外相关研究展开综述,汇总病例报告,以便更好地了解IL-17A抑制剂治疗银屑病相关皮损不良反应,为临床合理用药及治疗提供参考。

Psoriasis is a global challenge in skin diseases,and the development of IL-17A inhibitors has broken through the technical difficulties of psoriasis treatment,showing rapid and long-lasting efficacy,and has been widely recognized and applied.However,in clinical practice,some psoriasis patients may develop other skin diseases or diseases manifested as skin lesions after receiving IL-17A inhibitor treatment.We will now conduct a review of relevant research both domestically and internationally,summarizing case reports in order to better understand the adverse reactions of IL-17A inhibitors in the treatment of psoriasis related skin lesions and provide reference for rational drug use and treatment in clinical practice.